Patients With Gastroparesis Symptoms After Gastric Electrical Stimulation With and Without Tube Feedings.

NeuromodulationNov 26, 2025 (epub)
Clinical ResearchGastroenterology

Fares Kasem, Le Yu Naing, Prateek Mathur et al.

✦ AI-curated · Sources linked

In 30 seconds

This prospective, nonrandomized, open-label study compared gastric electrical stimulation (GES) outcomes in 311 patients with gastroparesis symptoms, with and without jejunostomy tube feedings. At one year, the authors reported significant relief of nausea, vomiting, and upper gastrointestinal symptoms, with improved tolerance of a regular diet in both groups. Responses were described as similar regardless of tube-feeding status, and patients maintained weight with or without a J-tube. The abstract does not provide numerical effect estimates for these outcomes.

Key findings

  • At one year after GES, nausea, vomiting, and upper gastrointestinal symptoms were significantly alleviated.
  • Patients with and without J-tube feedings had similar reported responses to GES.
  • Both groups had improved tolerance of a regular diet; weight was maintained with or without a J-tube.

Why it matters

Nutritional support needs can complicate care for patients with drug-refractory gastroparesis. These findings suggest that jejunostomy feeding and GES can coexist, while symptom relief and dietary tolerance may improve in patients in either group. The results may help inform discussions about GES when a patient has a J-tube, but they do not establish comparative efficacy.

What to keep in mind

The study was nonrandomized and open-label, and the abstract reports no numerical effect estimates. The one-year comparison cannot establish that GES caused the reported improvements.

Source

Published in Neuromodulation. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Gastroenterology

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.